Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Hepatocellular Carcinoma · Obesity

Hospital Authority

Hospital Authority, Hong Kong

Hospital Authority clinical programs — 322 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website
Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong, 852, HK, CN HQ
1991 Founded
12,669 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong, 852, HK, CN
Founded
1991
Employees
12,669
Programs
322
Drugs
301
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Hospital Authority projects

322 ClinicalTrials.gov programs sponsored by Hospital Authority.

Hospital Authority has 322 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

322 programs

Clinical programs

Page 3 of 7

  1. IN10018

    Hospital Authority, Hong Kong

    Cervical Adenocarcinoma

    phase 2 small molecule active

    1 trial

  2. Ivonescimab 20 mg/kg

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  3. Lenalidomide [Leavdo®]

    Hospital Authority, Hong Kong

    Antibiotics-unresponsive MALT Lymphoma

    phase 2 small molecule active

    1 trial

  4. Liposorber LA-15 System

    Hospital Authority, Hong Kong

    Cholesterol Embolism

    phase 2 other active

    1 trial

  5. MLC901

    Hospital Authority, Hong Kong

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  6. MSC and PRP

    Hospital Authority, Hong Kong

    Type 1 Diabetes Mellitus

    phase 2 mab active

    1 trial

  7. Morphine

    Hospital Authority, Hong Kong

    Respiratory Depression

    phase 2 small molecule active

    1 trial

  8. NK cells

    Hospital Authority, Hong Kong

    Hepatocellular Carcinoma

    phase 2 mab active

    1 trial

  9. Osteosheet(r)

    Hospital Authority, Hong Kong

    Orbital Trauma

    phase 2 other completed

    1 trial

  10. Pemebit

    Hospital Authority, Hong Kong

    Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  11. Placebo

    Hospital Authority, Hong Kong

    STOMACH NEOPLASM

    phase 2 small molecule active

    1 trial

  12. Quadriceps strength training

    Hospital Authority, Hong Kong

    Patellofemoral Pain Syndrome

    phase 2 other active

    1 trial

  13. Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine

    Hospital Authority, Hong Kong

    Advanced Tumors

    phase 2 other active

    1 trial

  14. Radio-guided sentinel node biopsy

    Hospital Authority, Hong Kong

    Cancer of the Breast

    phase 2 other terminated

    1 trial

  15. Repigel

    Hospital Authority, Hong Kong

    Acne

    phase 2 small molecule active

    1 trial

  16. Romiplostim N01

    Hospital Authority, Hong Kong

    Chemotherapy-induced Thrombocytopenia

    phase 2 small molecule active

    1 trial

  17. SHR-1210

    Hospital Authority, Hong Kong

    Renal Cell Carcinoma

    phase 2 mab active

    1 trial

  18. SNUBH-NM-333(18F)

    Hospital Authority, Hong Kong

    Alzheimer Disease

    phase 2 other terminated

    1 trial

  19. SS-1

    Hospital Authority, Hong Kong

    Sjögren's Syndrome

    phase 2 small molecule active

    1 trial

  20. Sarcosine and D-serine

    Hospital Authority, Hong Kong

    Schizophrenias

    phase 2 small molecule completed

    1 trial

  21. Sargramostim

    Hospital Authority, Hong Kong

    COVID

    phase 2 small molecule completed

    1 trial

  22. Sargramostim

    Hospital Authority, Hong Kong

    Pulmonary Alveolar Proteinosis, Autoimmune

    phase 2 small molecule completed

    1 trial

  23. Selinexor

    Hospital Authority, Hong Kong

    Acute Myeloid Leukemia, Adult

    phase 2 small molecule terminated

    1 trial

  24. Silodosin

    Hospital Authority, Hong Kong

    Premature Ejaculation

    phase 2 small molecule active

    1 trial

  25. Spironolactone 25mg

    Hospital Authority, Hong Kong

    Atrial Fibrillation

    phase 2 small molecule active

    1 trial

  26. TS-1 with cisplatin

    Hospital Authority, Hong Kong

    Recurrent Gastric Cancer

    phase 2 small molecule active

    1 trial

  27. Testosterone Enanthate 100 MG/ML Injectable Solution

    Hospital Authority, Hong Kong

    Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  28. Tislelizumab

    Hospital Authority, Hong Kong

    Pancreatic Neoplasms

    phase 2 small molecule active

    1 trial

  29. Tocilizumab

    Hospital Authority, Hong Kong

    Adamantinomatous Craniopharyngioma

    phase 2 small molecule active

    1 trial

  30. Transplantation of Autologous stem cell [MNCs] .

    Hospital Authority, Hong Kong

    Spinal Cord Injury.

    phase 2 mab active

    1 trial

  31. Trastuzumab in Combination with TS-ONE and cisplatin

    Hospital Authority, Hong Kong

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  32. Umbilical Cord Blood Infusion

    Hospital Authority, Hong Kong

    Cerebral Palsy

    phase 2 mab terminated

    1 trial

  33. Ursodeoxycholic acid

    Hospital Authority, Hong Kong

    Hepatitis D

    phase 2 small molecule active

    1 trial

  34. a standardized physical therapy program

    Hospital Authority, Hong Kong

    Frozen Shoulder

    phase 2 other completed

    1 trial

  35. acupuncture

    Hospital Authority, Hong Kong

    Peripheral Neuropathy Grade 2 or Greater

    phase 2 other terminated

    1 trial

  36. artesunate

    Hospital Authority, Hong Kong

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  37. autologous adipose-derived mesenchymal stem cell transplantation

    Hospital Authority, Hong Kong

    Aging Problems

    phase 2 mab active

    1 trial

  38. combination with Disitamab Vedotin and with Tislelizumab and Capecitabine

    Hospital Authority, Hong Kong

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  39. docetaxel and ketoconazole

    Hospital Authority, Hong Kong

    Metastatic Breast Cancer

    phase 2 small molecule completed

    1 trial

  40. doxorubicin, docetaxel

    Hospital Authority, Hong Kong

    Metastatic Breast Cancer

    phase 2 small molecule completed

    1 trial

  41. nitric oxide gel

    Hospital Authority, Hong Kong

    Neuropathic Pain

    phase 2 small molecule completed

    1 trial

  42. paclitaxel/carboplatin/lapatinib

    Hospital Authority, Hong Kong

    ErbB2-Positive Stage I-III Breast Cancer

    phase 2 small molecule active

    1 trial

  43. pembrolizumab

    Hospital Authority, Hong Kong

    Locally Recurrent Cancer

    phase 2 small molecule active

    1 trial

  44. real-tDCS with MI-BCI

    Hospital Authority, Hong Kong

    Stroke

    phase 2 other completed

    1 trial

  45. remicade (anti tumor necrosis factor inhibitor)

    Hospital Authority, Hong Kong

    Takayasu's Arteritis

    phase 2 small molecule active

    1 trial

  46. AZD5363+Olaparib+Durvalumab

    Hospital Authority, Hong Kong

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  47. Autologous Natural Killer Cell Therapy

    Hospital Authority, Hong Kong

    Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  48. Biological: PD-1

    Hospital Authority, Hong Kong

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Hospital Authority have?

322 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.